Breadcrumb

Breadcrumbs

Press Releases

Press Releases

News, Events, Updates, Breakthroughs

Journalists may direct questions to mediainquiries@dsi.com. Or click here for direct contact information for Daiichi Sankyo U.S. Public Affairs team

Press announcements are archived by release date, searchable by topic:

From To
Date Title
2020.10.22
Daiichi Sankyo Initiates Phase 1 Trial with Immuno-Oncology Therapy DS-1055 Targeting GARP on Activ ...
PDF (125 KB)
2020.09.25
ENHERTU® Approved in Japan for the Treatment of Patients with HER2 Positive Metastatic Gastric Can ...
PDF (230 KB)
2020.09.18
Daiichi Sankyo Announces Late-Breaking Phase 1 Dose Expansion Data for Patritumab Deruxtecan in Pat ...
PDF (251 KB)
2020.09.14
Daiichi Sankyo Initiates Phase 2 Study of Patritumab Deruxtecan in Patients with HER3 Expressing Ad ...
PDF (140 KB)
2020.09.09
Late-Breaking Data for Daiichi Sankyo’s HER3 Directed ADC Patritumab Deruxtecan in EGFR Mutated NSC ...
PDF (190 KB)
2020.08.06
Daiichi Sankyo Announces Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Derux ...
PDF (133 KB)
2020.07.27
Daiichi Sankyo and AstraZeneca Enter New Global Development and Commercialization Collaboration for ...
PDF (200 KB)
2020.07.22
Daiichi Sankyo and Gustave Roussy Enter Innovative Research Collaboration for DXd ADCs DS-1062 and ...
PDF (167 KB)
2020.07.01
Daiichi Sankyo Expands DS-1062 Study to Include Patients with Triple Negative Breast Cancer
PDF (155 KB)
2020.05.29
ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastati ...
PDF (246 KB)
Showing 1 - 10 of 34 results.

Press Release More Stories

More Stories

Who We Are

As the U.S. subsidiary of a global pharmaceutical innovator, Daiichi Sankyo, Inc. draws on a rich heritage of innovation, integrity and accountability..

read more ...